ArticleMMWR. Morbidity and mortality weekly report2021
Distribution of SARS-CoV-2 Variants in a Large Integrated Health Care System - California, March-July 2021.
Article in MMWR. Morbidity and mortality weekly report, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Real-Time Monitoring of SARS-CoV-2 Variants in Oklahoma Wastewater through Allele-Specific RT-qPCR.Microorganisms · 2024Article
- Health equity in COVID-19 testing among patients of a large national pharmacy chain.Frontiers in public health · 2024Article
- Factors affecting SARS-CoV-2 variant distribution in military hospitals in Jordan.Diagnostic microbiology and infectious disease · 2022Article
- A Robust, Highly Multiplexed Mass Spectrometry Assay to Identify SARS-CoV-2 Variants.Microbiology spectrum · 2022Article
- RT-PCR/MALDI-TOF Diagnostic Target Performance Reflects Circulating SARS-CoV-2 Variant Diversity in New York City.The Journal of molecular diagnostics : JMD · 2022Article
- Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences.Vaccines · 2022Review
- A robust, highly multiplexed mass spectrometry assay to identify SARS-CoV-2 variants.medRxiv : the preprint server for health sciences · 2022Article
- Genomic characterization of SARS-CoV-2 from vaccine breakthrough cases in Allegheny County, Pennsylvania.PloS one · 2022Article
- Missing science: A scoping study of COVID-19 epidemiological data in the United States.PloS one · 2022Article
- Dynamic characteristics of COVID-19 infection in Chinese children.American journal of translational research · 2022Article
- Characterizing the Severity of SARS-CoV-2 Variants at a Single Pediatric Center.Frontiers in medicine · 2022Article
- Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study.PloS one · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Data from observational studies demonstrate that variants of SARS-CoV-2, the virus that causes COVID-19, have evolved rapidly across many countries (1,2). The SARS-CoV-2 B.1.617.2 (Delta) variant of concern is more transmissible than previously identified variants,* and as of September 2021, is the predominant variant in the United States.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.